Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
173
datasets available to search
ShareScore release 0.9.0
Dataset results
173 results for “hypogonadism”
Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men
ClinicalTrials.gov study NCT01200862. IPD Sharing: NO. Countries: 2. Publications: 0.
Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™
ClinicalTrials.gov study NCT02937740. IPD Sharing: NO. Countries: 1. Publications: 0.
LutrePulse Hypogonadotropic Hypogonadism
ClinicalTrials.gov study NCT01976728. IPD Sharing: Not stated. Countries: 2. Publications: 0.
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
ClinicalTrials.gov study NCT04456296. IPD Sharing: YES. Countries: 1. Publications: 0.
Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men
ClinicalTrials.gov study NCT01104246. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy
ClinicalTrials.gov study NCT01061970. IPD Sharing: Not stated. Countries: 0. Publications: 10.
Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
ClinicalTrials.gov study NCT01534208. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism
ClinicalTrials.gov study NCT02081300. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Data from: Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy
Open the record for dataset details and reuse information.
Hypogonadism and Neurocognitive Outcomes among Childhood Cancer Survivors
<h2>Abstract</h2> <div> <div><strong>Objective</strong></div> <p>Childhood cancer survivors are at risk for hypogonadism. Impact of hypogonadism on neurocognitive impairment and emotional distress in the non-cancer population has been shown, however, the relationship among childhood cancer survivor population is unknown. We aimed to evaluate the contribution of hypogonadism to neurocognitive impairment and emotional distress among survivors.</p> </div> <div> <div><strong>Design</strong></div> <p>Cross-sectional study using retrospective cohort.</p> </div> <div> <div><strong>Methods</strong></div> <p>3628 survivors who completed standard neurocognitive tests (six domains: processing speed, memory, executive function, attention, academics, global cognition) and self-reported emotional distress were included in our study. Participants were stratified by sex and gonadal status. Outcomes were compared between hypogonadal and eugonadal groups by multivariable analysis, adjusting for established predictors, and mediation analyses to determine the direct/indirect effects of hypogonadism on outcomes.</p> </div> <div> <div><strong>Results</strong></div> <p>The hypogonadal group exhibited higher prevalence of neurocognitive impairment across domains, but no difference in emotional distress. Hypogonadal females exhibited higher relative risk (1.7, 95% confidence interval 1.2–2.5) for impaired visual processing speed, compared to eugonadal females after adjusting for cancer-related variables. In mediation models, hypogonadism had significant direct (<em>P</em> < 0.01) and indirect (from <em>P</em> < 0.01) impact on impairment in visual processing speed among females. Males demonstrated direct (<em>P</em> =0.03) and indirect (<em>P</em> =0.04) impact of hypogonadism on motor processing speed.</p> </div> <div> <div><strong>Conclusion</strong></div> <p>Processing speed may be the most vulnerable neurocognitive domain associated with hypogonadism in survivors, while other domains were mainly impacted by cancer-related variables. Our findings support the need for further evaluation of the impact of sex hormone replacement therapy on neurocognitive function.</p> </div>
The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population
ClinicalTrials.gov study NCT06247267. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
ClinicalTrials.gov study NCT00838838. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effects of Medications in Patients With Hypogonadism
ClinicalTrials.gov study NCT01601327. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment
ClinicalTrials.gov study NCT02111434. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction
ClinicalTrials.gov study NCT02803073. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial
ClinicalTrials.gov study NCT00260390. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate
ClinicalTrials.gov study NCT00555087. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism
ClinicalTrials.gov study NCT00193661. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks
ClinicalTrials.gov study NCT00710827. IPD Sharing: Not stated. Countries: 6. Publications: 0.
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months
ClinicalTrials.gov study NCT06385509. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.